Document is current

Article History

Received: 15 February 2022

Accepted: 10 May 2022

First Online: 15 June 2022

Change Date: 23 June 2022

Change Type: Update

Change Details: In the version of this article initially published, in the last sentence of the “LDL lowering beyond statins” section, the text now reading “Obicetrapib, a potent CETP inhibitor, can lower LDL-C by about 50%” originally read “5%” in the HTML version of the article. This technical error has been amended in the HTML version of this article.

Competing interests

: L.T. reports consulting fees from Abbott, Amgen, Bayer, MSD, Mylan, Novartis, Sanofi, and Daiichi-Sankyo; payment or honoraria from Abbott, Janssen, Amgen, Bayer, Daiichi-Sankyo, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati Abdi-İbrahim; support for attending meetings for Servier; participation on a data safety monitoring board or advisory board for Abbott, Amgen, Novartis, Sanofi, Daiichi-Sankyo, Mylan, Pfizer. L.T. was the Past President European Atherosclerosis Society and the Past President Turkish Society of Cardiology. P.L. is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron. P.L. is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, Soley Therapeutics, TenSixteen Bio, and XBiotech, Inc. P.L.’s laboratory has received research funding in the last 2 years from Novartis. P.L. is on the Board of Directors of XBiotech, Inc. P.L. has a financial interest in Xbiotech, a company developing therapeutic human antibodies, and in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. P.L.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict-of-interest policies.